Good piece, although Mr Joshi has done worse than claiming we are the best. Including pushing favipiravir and Itolizumab, despite conflicts of interest.
While being an advisor to Biocon, he was also on Mumbai's Covid task force, which continues to prescribe Itolizumab.
How does one appear in a company's press conference for the launch of a drug, claim it is wonderful, and then also be a part of a state task force that prescribes the drug? Same applies to another noted pulmonologist.
Forgot to mention: claim it is wonderful based on a 30 patient study that was so badly done that it never made it past peer review. Till date, it remains a preprint.

• • •

Missing some Tweet in this thread? You can try to force a refresh
 

Keep Current with PriyankaPulla

PriyankaPulla Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @PriyankaPulla

28 Apr
Someone I don't know from Adam wrote this email to Anvisa, demanding to know why they approved Sinovac, and not Sputnik/Covaxin, and marked me on it.
Naturally, I wasn't marked on any letter to CDSCO, demanding to know why Anvisa was saying what it is.
More from the genius. Pay particular attention to the part about how "most Indian companies probably don't follow GMP" and how Indian GMP is different from Western GMP 😂
Read 4 tweets
26 Apr
It seems like some of the unused doses of the AZ vaccine in USA were made in the Emergent Biosolutions plant, which was later found to have mixed up ingredients between AZ and J&J vaccine nytimes.com/2021/03/11/us/…
In discussions to import these doses, India must make sure that these doses were untouched by the significant manufacturing problems.
Read 4 tweets
16 Apr
Kinetics of inactivation and validation of proof of inactivation happen at multiple stages - during development and while scaling to manufacture. The jump in scale from development to manufacture is huge, and the whole process *must* be repeated
Simple example: The kinetics of inactivation that Jonas Salk plotted while developing the vaccine didn't work when it was scaled to manufacture. *A lot changes* during large scale production, including methods of inactivation. Repeated validation is *required*
So, *no*. The kinetics of inactivation you see in the Cell paper cannot be extrapolated to commercial manufacturing. And yes, I did see that paper.
Read 4 tweets
16 Apr
[New story] Two weeks ago, the Brazilian regulator Anvisa published a report listing a number of quality control problems with Covaxin, including that the company hadn't "validated the method to prove complete inactivation of the virus". thequint.com/coronavirus/ex…
The report looked pretty serious at first look. And yet, some commentators said the Anvisa's complaints were just a "bureaucratic" issue, or "just a documentation problem".
I spoke to Good Manufacturing Practices experts (people who routinely see such reports) to understand exactly what each term in the Anvisa report meant.
Read 5 tweets
8 Apr
Many in India may be confused about MHRA's decision yesterday to offer an alternative to the AZ vaccine in under-30 year olds. What does this mean for Covishield and you? The following three slides should help understand things more clearly (1)
First: a slide shared at MHRA PC comparing benefits and risks of vaccine in low prevalence regions. Explains most clearly why the vaccine may not be the best choice for under 30 y.o. *when transmission is low*. For everyone else, benefit>risk (2)
Second: a slide of benefit/risk comparison in a region with medium prevalence. Here, already, the benefits for even under 30 y.o start to outweigh risk of clots. For everyone else, the ratio is even more favourable (3)
Read 7 tweets
31 Mar
The 23 March 2021 COVID treatment guidelines of Maharashtra govt, as the state sees a huge surge. Vitamin D, Favipiravir and HCQ reccomended for mild cases
Convalescent plasma for moderate and severe
Favi, Vit C, Vit D, Zinc etc for moderate cases
Read 5 tweets

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Too expensive? Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal Become our Patreon

Thank you for your support!

Follow Us on Twitter!